Search results
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 10 hours agoDespite a bevy of promising updates for its cancer treatments, Pfizer stock remains trapped below a...
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
Reuters via Yahoo News· 3 hours agoA 15-day course of Pfizer's COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long...
Thinking Of Buying Pfizer For Its 5.8% Dividend Yield? Consider This Alternative Option Instead
Benzinga via Yahoo Finance· 8 hours agoPfizer Inc. (NYSE:PFE) has long been a favorite among income investors, thanks to its generous...
Paxlovid Fails to Quell Long Covid Symptoms in Stanford Study
Bloomberg· 3 hours agoA 15-day course of Pfizer Inc.’s antiviral Paxlovid didn’t provide significant relief for long Covid...
Pfizer: New Cancer Drugs Could Breathe New Life Into Struggling Pharma Behemoth
Investing.com· 3 days agoPharmaceutical stocks, once pandemic favorites, have faced significant corrections. Despite broader...
US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59
Reuters via Yahoo News· 19 minutes agoThe shot, branded Arexvy, as well as vaccines from rivals Pfizer and Moderna are already approved...
2 Dividend Stocks Billionaires Are Buying: Should You?
Motley Fool via Yahoo Finance· 9 hours agoIt's essential to do some research of our own. With that said, let's look at two dividend stocks...
New COVID variant KP.3 climbs to 25%, now largest in CDC estimates
CBS News· 6 hours agoThe new KP.3 variant has climbed to 1 in 4 new COVID-19 cases nationwide, the Centers for Disease...
What to know about upcoming COVID-19 vaccines and the FLiRT variants
GBH News· 10 hours agoThe federal government and vaccine makers are getting a new COVID-19 vaccine ready for the fall. An...
Updated Covid-19 Vaccine Targeting JN.1 Recommended By FDA Panel
Forbes· 3 days agoThe Vaccines and Related Biological Products Advisory Committee of the FDA evaluated the...